Q2
AVBP — Q2 2026 Financial Report Analysis
ArriVent's Q2 2026 net loss widened to $49.9M as ADC spending more than tripled; it held $373.1M in cash after $140M of stock sales — then its Phase 3 FURVENT trial missed its primary endpoint on October 6.